2014
Novel Combination Markers for Predicting Survival in Patients with Muscle Invasive Bladder Cancer: USP18 and DGCR2
Kim Y, Kim W, Jeong P, Ha Y, Kang H, Yun S, Moon S, Choi Y, Kim I, Kim W. Novel Combination Markers for Predicting Survival in Patients with Muscle Invasive Bladder Cancer: USP18 and DGCR2. Journal Of Korean Medical Science 2014, 29: 351-356. PMID: 24616583, PMCID: PMC3945129, DOI: 10.3346/jkms.2014.29.3.351.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkersCarrier ProteinsEndopeptidasesFemaleGene Expression ProfilingHumansKaplan-Meier EstimateMaleMiddle AgedMuscle NeoplasmsNeoplasm InvasivenessNeoplasm StagingPlatelet Glycoprotein GPIb-IX ComplexPredictive Value of TestsRegression AnalysisRisk FactorsROC CurveUbiquitin ThiolesteraseUrinary Bladder NeoplasmsConceptsCancer-specific survivalCancer-specific deathBladder cancer patientsHigh expression groupExpression of USP18MIBC patientsCancer patientsExpression groupMuscle-invasive bladder cancer patientsCancer-specific survival ratesInvasive bladder cancer patientsMuscle-invasive bladder cancerLonger cancer-specific survivalMultivariate Cox regression analysisCox regression analysisInvasive bladder cancerSignificant risk factorsReliable prognostic markersMRNA expression levelsSurvival-related genesOverall survivalValidation cohortOriginal cohortLonger survivalPredicting SurvivalDiagnosis of bladder cancer and prediction of survival by urinary metabolomics
Jin X, Yun S, Jeong P, Kim I, Kim W, Park S. Diagnosis of bladder cancer and prediction of survival by urinary metabolomics. Oncotarget 2014, 5: 1635-1645. PMID: 24721970, PMCID: PMC4039236, DOI: 10.18632/oncotarget.1744.Peer-Reviewed Original ResearchConceptsBladder cancerControl groupCancer groupCancer-specific survival timeMuscle-invasive bladder cancerInvasive bladder cancerMetabolomic profilesPrediction of survivalHigh-performance liquid chromatography-quadrupole timeLiquid chromatography-quadrupole timeUrinary metabolomicsCommon cancerControl subjectsUrinary cytologyBC diagnosisDiagnostic modalitiesSurvival timeCurrent modalitiesUrine metabolitesMetabolomics-based approachPatientsCancerDifferential metabolitesClinical applicabilityCarnitine transferase
2011
A Four-Gene Signature Predicts Disease Progression in Muscle Invasive Bladder Cancer
Kim W, Kim S, Jeong P, Yun S, Cho I, Kim I, Moon S, Um H, Choi Y. A Four-Gene Signature Predicts Disease Progression in Muscle Invasive Bladder Cancer. Molecular Medicine 2011, 17: 478-485. PMID: 21308147, PMCID: PMC3105150, DOI: 10.2119/molmed.2010.00274.Peer-Reviewed Original ResearchConceptsMuscle-invasive bladder cancerFour-gene signatureInvasive bladder cancerDisease progressionMIBC patientsMIBC progressionBladder cancerIndependent cohortMultivariate Cox regression analysisCox regression analysisReal-time reverse transcriptase-polymerase chain reactionReverse transcriptase-polymerase chain reactionTranscriptase-polymerase chain reactionGene expression signaturesIndependent predictorsPatient survivalPrognostic valuePromising diagnostic toolPolymerase chain reactionHigh riskPredictive valueMicroarray gene expression profilingImportant mediatorPatientsGene expression profiling
2010
Tissue hOGG1 Genotype Predicts Bladder Cancer Prognosis: A Novel Approach Using a Peptide Nucleic Acid Clamping Method
Ha Y, Yan C, Kim I, Yun S, Moon S, Kim W. Tissue hOGG1 Genotype Predicts Bladder Cancer Prognosis: A Novel Approach Using a Peptide Nucleic Acid Clamping Method. Annals Of Surgical Oncology 2010, 18: 1775-1781. PMID: 21184188, DOI: 10.1245/s10434-010-1500-7.Peer-Reviewed Original ResearchConceptsMuscle-invasive bladder cancerBladder cancerPolymerase chain reactionNonmuscle invasive bladder cancer patientsHOGG1 codon 326 genotypesProgression-free survival benefitInvasive bladder cancer patientsTumor tissueTissue genotypeHOGG1 codon 326Primary BC patientsCox regression analysisInvasive bladder cancerBladder cancer prognosisPrimary bladder cancerAggressive clinicopathological featuresBladder cancer patientsReal-time polymerase chain reactionSurvival benefitBC prognosisClinicopathological characteristicsClinicopathological featuresBC patientsPrognostic indicatorCancer patients